Form 4: Lemaitre Vascular Director Accrues Additional Dividend Equivalent Rights

Martha Shadan, a Director at Lemaitre Vascular Inc. (LMAT), reported the accrual of additional dividend equivalent rights tied to her existing restricted stock and performance share unit awards.

Summary

• Martha Shadan, a Director of Lemaitre Vascular Inc. (LMAT), filed a Form 4 reporting changes in her beneficial ownership.
• On May 29, 2025, Ms. Shadan acquired 0.4985 Dividend Equivalent Rights (DERs) related to a restricted stock unit (RSU) award granted on December 12, 2022.
• Additionally, on May 29, 2025, she acquired 0.4985 DERs linked to a Performance Share Unit (PSU) award granted on December 12, 2022.
• Further acquisitions on May 29, 2025, included 0.8524 DERs from an RSU award granted on December 8, 2023, and 1.0208 DERs from a PSU award granted on December 8, 2023.
• A final acquisition on May 29, 2025, involved 1.0387 DERs associated with an RSU award granted on December 6, 2024.
• Each Dividend Equivalent Right is the economic equivalent of one share of Lemaitre Vascular's common stock and vests proportionately with its underlying award.
• Following these transactions, Ms. Shadan directly holds 6.0983, 5.1096, 4.6837, 5.0145, and 2.0397 Dividend Equivalent Rights from the respective awards.

Sentiment

Score: 6

Explanation: The sentiment is slightly positive as it indicates a director's continued accumulation of equity-linked compensation, aligning their interests with shareholders. However, it's a routine filing and not a significant market-moving event.

Positives

• The accrual of Dividend Equivalent Rights aligns the director's interests with shareholders, as these rights are tied to the company's common stock and vest with existing equity awards.
• This is a routine compensation-related transaction, indicating stability in executive compensation practices.

Risks

• The value of these dividend equivalent rights is directly tied to the performance of Lemaitre Vascular's common stock, exposing the holder to market fluctuations.

Future Outlook

This Form 4 filing does not contain any forward-looking statements or guidance regarding the company's future financial performance or strategic direction.

Industry Context

This filing is a standard disclosure of an insider's equity-based compensation and does not provide specific insights into broader industry trends within the medical device or vascular health sector. It reflects routine corporate governance and executive compensation practices.

Stakeholder Impact

• Shareholders: The accrual of dividend equivalent rights by a director can be viewed positively as it increases insider ownership and aligns management's interests with long-term shareholder value, although the immediate impact is minimal due to the small number of rights.

Next Steps

• The Dividend Equivalent Rights will vest proportionately with their underlying Restricted Stock Unit (RSU) and Performance Share Unit (PSU) awards.
• Upon vesting, these rights will convert into shares of Lemaitre Vascular's common stock.

Key Dates

Recommendation

Keywords

SEC Form 4, Insider Transaction, Beneficial Ownership, Dividend Equivalent Rights, Restricted Stock Units, Performance Share Units, Lemaitre Vascular, LMAT, Executive Compensation, Corporate Governance